Flashback Foreword: KRAS Is a Selection Marker for Panitumumab Benefit in Patients With Metastatic Colorectal Cancer

Abstract

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES JCO Flashback: Predictive Value of KRAS Mutations on the Outcomes of Panitumumab Monotherapy in Colorectal Cancer. June 14, 2023 Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. June 14, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00221 Journal of Clinical Oncology - published online before print June 14, 2023 PMID: 37315388 Flashback Foreword: KRAS Is a Selection Marker for Panitumumab Benefit in Patients With Metastatic Colorectal Cancer Andrew H. Ko, MD1,2xAndrew H. KoSearch for articles by this author Show More 1Associate Editor, Journal of Clinical Oncology, Alexandria, VA2University of California San Francisco Cancer Center, San Francisco, CA https://doi.org/10.1200/JCO.23.00221 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2008, Amado et al1 published a biomarker analysis demonstrating the negative predictive value of KRAS mutations for outcome of antiepidermal growth factor receptor therapy in patients with advanced colorectal cancer. These findings guide treatment decision making for colorectal cancer that continues up to the present time and also informed further discoveries relating to treatment resistance and approaches to monitoring for this disease.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: KRAS Is a Selection Marker for Panitumumab Benefit in Patients With Metastatic Colorectal CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Andrew H. KoThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Honoraria: Research to Practice, Clinical Care Options, Medscape, BioAscent, MJH Life Sciences, Gerson Lehrman GroupConsulting or Advisory Role: ERYTECH Pharma, Imugene, SynCoreBio, Roche/Genentech, Ipsen, Five Prime Therapeutics, Tyme, Turning Point Therapeutics, Signatera, Syros PharmaceuticalsSpeakers' Bureau: Clinical Care OptionsResearch Funding: Celgene (Inst), Merck (Inst), Genentech/Roche (Inst), Bristol Myers Squibb (Inst), AbGenomics International (Inst), Apexigen (Inst), Astellas Pharma (Inst), Leap Therapeutics (Inst), BioMed Valley Discoveries (Inst), CrystalGenomics (Inst)No other potential conflicts of interest were reported. Companion JCO Flashback: Predictive Value of KRAS Mutations on the Outcomes of Panitumumab Monotherapy in Colorectal Cancer Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer